JPMorgan raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $22.00 (from $19.00) while maintaining a Overweight rating.

Analyst PT Change

Halozyme Therapeutics (HALO) PT Raised to $19 at BMO CapitalFebruary 21, 2018 8:42 AM Halozyme Therapeutics (HALO) PT Raised to $24 at Deutsche BankFebruary 21, 2018 6:55 AM Halozyme Therapeutics (HALO) PT Raised to $21 at Canaccord GenuityFebruary 21, 2018 5:12 AM Halozyme Therapeutics (HALO) PT Raised to $21 at JMP SecuritiesFebruary 21, 2018 4:34 AM Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates OutlookFebruary 20, 2018 4:07 PM